The 2018 midterm elections are just days away and the outcomes of those contests could affect an array of sectors and industries. Currently, most political prognosticators are forecasting the Democrats gaining control of the House while the Republicans are expected to maintain control of the Senate.
Healthcare, one of this year’s stronger sectors, is a group historically impacted by events on Capitol Hill. Industry exchange traded funds, such as the SPDR S&P Health Care Services ETF (NYSEArca: XHS), could be in focus following the midterm elections.
XHS covers companies in the sub-industries involved in Health Care Distributors, Health Care Facilities, Health Care Services, and Managed Health Care, and it follows a more equally weighted indexing methodology.
“If Republicans maintain majority control of the House and increase their Senate majority by at least one seat, they would likely have the votes to pass more substantial reform or repeal the Affordable Care Act (ACA) in its entirety,” said State Street Global Advisors (SSgA) in a note out Wednesday.
To that point, XHS could rally if the Democrats gain control of both the House and Senate.
Other Healthcare Industry Ideas
“Drug pricing reform continues to be a hot topic for the president. While unique in its potential to drum up bi-partisan support, to date Congress has focused only on pharmacy benefit managers (PBMs). A bill to ban pharmacy gag clauses currently sits on the president’s desk for signature,” according to SSgA.
Republicans maintaining control of both houses of Congress could favor the SPDR Pharmaceuticals ETF (NYSEArca: XPH).
Some expectations point to Democrats winning back the House of Representatives and the Republicans maintaining a narrow hold on the Senate – Republicans currently dominate both chambers. According to public opinion polls, it would require a sea change to alter current projections, CNBC reports.
“If Democrats gain control of both houses, pressure could shift from PBMs to directly target pharmaceutical firms through measures like increased imports, broadening the availability of generics, and the passage of the FAIR drug pricing act that would require manufacturers to publicly justify their price levels,” said SSgA.
For more information on the market sectors, visit our sector ETFs category.